Melior Discovery inflammation/arthritis
LPS Model of Systemic Inflammation
Bolus injection of lipopolysaccharide (LPS) the major component of bacterial cell wall, results in the rapid and transient rise in tumor necrosis factor (TNFα) levels in serum in mammals. This animal model was originally developed to mirror certain aspects of septic shock in humans. This model may be an effective first-line general inflammation model and may be used to determine the anti-inflammatory potential of test compounds. A variety of clinically approved anti-inflammatory compounds are extremely effective in this model including glucocorticoids, NSAIDS and cox-2 inhibitors.
Following a bolus injection of LPS, blood was collected from animals and serum was isolated. LPS injection induced a significant increase in TNF-a in vehicle treated animals. Oral administration of dexamethasone, a potent anti-inflammatory, significantly attenuated the TNF-a indicating a prevention of the inflammation response. These results are similar to literature reports (Ochalski et al., 1993; Zuckerman et al., 1989). Data are mean serum concentrations ± SEM; *p<0.05.
If you are interested in learning more about the LPS Model of Systemic Inflammation, please contact email@example.com to start the conversation.